These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 9043731

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.
    Audhuy B, Cappelaere P, Martin M, Cervantes A, Fabbro M, Rivière A, Khayat D, Bleiberg H, Faraldi M, Claverie N, Aranda E, Auclerc G, Audhuy B, Benhammouda A, Bleiberg H, Cals L, Cappelaere P, Cattan A, Cervantes A, Chevallier B, Conroy T, Cupissol D, De Grève J, Diaz-Rubio E, Seitz JF.
    Eur J Cancer; 1996 May; 32A(5):807-13. PubMed ID: 9081358
    [Abstract] [Full Text] [Related]

  • 3. Intravenous dolasetron mesilate in the prevention of postoperative nausea and vomiting in females undergoing gynecological surgery.
    Diemunsch P, D'Hollander A, Paxton L, Schoeffler P, Wessel P, Navé S, Brown RA, Hahne WF.
    J Clin Anesth; 1997 Aug; 9(5):365-73. PubMed ID: 9257201
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Treatment of postoperative nausea and vomiting with single intravenous doses of dolasetron mesylate: a multicenter trial. Dolasetron Mesylate PONV Treatment Study Group.
    Kovac AL, Scuderi PE, Boerner TF, Chelly JE, Goldberg ME, Hantler CB, Hahne WF, Brown RA.
    Anesth Analg; 1997 Sep; 85(3):546-52. PubMed ID: 9296407
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.
    Chevallier B, Cappelaere P, Splinter T, Fabbro M, Wendling JL, Cals L, Catimel G, Giovannini M, Khayat D, Bastit P, Claverie N.
    Support Care Cancer; 1997 Jan; 5(1):22-30. PubMed ID: 9010986
    [Abstract] [Full Text] [Related]

  • 9. Oral dolasetron mesylate for prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study. The Oral Dolasetron PONV Prevention Study Group.
    Diemunsch P, Korttila K, Leeser J, Helmers JH, Wilkey B, Navé S, Radke AJ, Hahne WF, Brown RA.
    J Clin Anesth; 1998 Mar; 10(2):145-52. PubMed ID: 9524901
    [Abstract] [Full Text] [Related]

  • 10. A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients.
    Bey P, Wilkinson PM, Resbeut M, Bourdin S, Le Floch O, Hahne W, Claverie N.
    Support Care Cancer; 1996 Sep; 4(5):378-83. PubMed ID: 8883232
    [Abstract] [Full Text] [Related]

  • 11. A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis.
    Harman GS, Omura GA, Ryan K, Hainsworth JD, Cramer MB, Hahne WF.
    Cancer Chemother Pharmacol; 1996 Sep; 38(4):323-8. PubMed ID: 8674154
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
    Hesketh P, Navari R, Grote T, Gralla R, Hainsworth J, Kris M, Anthony L, Khojasteh A, Tapazoglou E, Benedict C, Hahne W.
    J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pooled analysis of three large clinical trials to determine the optimal dose of dolasetron mesylate needed to prevent postoperative nausea and vomiting. The Dolasetron Prophylaxis Study Group.
    Philip BK, McLeskey CH, Chelly JE, McKenzie R, Kovac AL, Diemunsch P, DuBois DM.
    J Clin Anesth; 2000 Feb; 12(1):1-8. PubMed ID: 10773500
    [Abstract] [Full Text] [Related]

  • 17. Timing of administration of dolasetron affects dose necessary to prevent postoperative nausea and vomiting.
    Korttila KT, Jokinen JD.
    J Clin Anesth; 2004 Aug; 16(5):364-70. PubMed ID: 15374558
    [Abstract] [Full Text] [Related]

  • 18. The effect of timing of dolasetron administration on its efficacy as a prophylactic antiemetic in the ambulatory setting.
    Chen X, Tang J, White PF, Wender RH, Quon R, Sloninsky A, Naruse R, Kariger R, Webb T, Norel E.
    Anesth Analg; 2001 Oct; 93(4):906-11. PubMed ID: 11574355
    [Abstract] [Full Text] [Related]

  • 19. Dolasetron for the prevention of postoperative nausea and vomiting following outpatient surgery with general anaesthesia: a randomized, placebo-controlled study. The Dolasetron PONV Prevention Study Group.
    Philip BK, Pearman MH, Kovac AL, Chelly JE, Wetchler BV, McKenzie R, Monk TG, Dershwitz M, Mingus M, Sung YF, Hahne WF, Brown RA.
    Eur J Anaesthesiol; 2000 Jan; 17(1):23-32. PubMed ID: 10758440
    [Abstract] [Full Text] [Related]

  • 20. Single-dose, placebo-controlled, phase I study of oral dolasetron.
    Dixon RM, Cramer M, Shah AK, Whitmore J, Benedict CR, Hahne WF.
    Pharmacotherapy; 1996 Jan; 16(2):245-52. PubMed ID: 8820468
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.